Zhongji Health (000972) disclosed its 2026 semi-annual report on August 29. In the first half of the year, it achieved total operating revenue of 197 million yuan, down 19.65 percent year on year. Net profit attributable to the parent company was a loss of 65.919 million yuan, compared with a loss of 74.7031 million yuan in the same period last year. Net profit after deducting non-recurring items was a loss of 74.66 million yuan, compared with a loss of 79.3333 million yuan a year earlier. Net cash flow from operating activities was 127 million yuan, compared with minus 101 million yuan in the prior-year period. Basic earnings per share were minus 0.0855 yuan. The company's main business is the research, development, manufacturing and sales of bulk-packaged tomato paste, small-packaged tomato products, lycopene soft capsules and other products. As of the end of the first half, the company's inventory decreased by 65.73 percent from the end of last year, prepayments increased by 260.53 percent, short-term borrowings decreased by 20.82 percent, and contract liabilities decreased by 39.28 percent.
Xinjiang Chalkis Co LtdCompany reported a net loss of 65.919 million yuan in H1 2026, though loss narrowed from prior year.
